about
Regular physical activity and risk of atrial fibrillation: a systematic review and meta-analysisSecurity and privacy qualities of medical devices: an analysis of FDA postmarket surveillanceImproved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair.Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research.Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry.Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure.Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators.The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011.Trends in utilization and complications of catheter ablation for atrial fibrillation in Medicare beneficiaries.Non-inducibility post-pulmonary vein isolation achieving exit block predicts freedom from atrial fibrillationPredictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial.Current clinical characteristics and economic impact of subacute stent thrombosis.Cost-effectiveness of supervised exercise, stenting, and optimal medical care for claudication: results from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial.MADIT II (second Multicenter Automated Defibrillator Implantation Trial) debate: risk stratification, costs, and public policy.Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study.A cost-minimization analysis of the angio-seal vascular closure device following percutaneous coronary intervention.Bi-directional electrical pulmonary vein isolation as an endpoint for ablation of paroxysmal atrial fibrillation.Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry.Health Status After Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Increased Surgical Risk: Results From the CoreValve US Pivotal Trial.Patient Activity and Survival Following Implantable Cardioverter-Defibrillator Implantation: The ALTITUDE Activity Study.Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients.Correlation of patient-reported symptom outcomes and treadmill test outcomes after treatment for aortoiliac claudication.Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model.Utilization and likelihood of radiologic diagnostic imaging in patients with implantable cardiac defibrillatorsCost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosisProphylactic catheter ablation for the prevention of defibrillator therapyTemporal Trends in Quality of Life Outcomes After Transapical Transcatheter Aortic Valve Replacement: A Placement of AoRTic TraNscathetER Valve (PARTNER) Trial Substudy.Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation.Resynchronization: considering device-based cardiac therapy in older adults.The frequency and cost of complications associated with coronary artery bypass grafting surgery: results from the United States Medicare program.Inducibility of atrial fibrillation with a synchronized external low energy shock post-pulmonary vein isolation predicts recurrent atrial fibrillation.Body Mass Index, Quality of Life, and Catheter Ablation in Patients with Atrial Fibrillation.Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study.Cost-effectiveness of transcatheter valvular interventions: economic challenges.Cost-effectiveness considerations in transcatheter management of valvular heart disease.Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B).Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs.Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.Healthcare Utilization and Expenditures Associated With Appropriate and Inappropriate Implantable Defibrillator Shocks.
P50
Q27009401-027220E9-591B-4665-8D70-877764871FF3Q28481425-93628344-649C-40CA-975A-E23A46F7F9F3Q30457109-5526819F-86F4-495A-84EF-5D955197864EQ30692570-0EA91B5E-25C9-4726-B699-335AF7B85394Q30839954-1E152C21-6955-4969-B3F4-1CB970623DD0Q33637073-0BF56A2C-065C-4448-BA6B-7B3F969C423FQ34011330-ED72D8B1-F561-40E5-B2BC-F99DEBAAE080Q34035537-BE9FB574-5B4F-4789-8043-92B38E9E5B13Q34220185-7BD19417-7369-4391-B383-67777271BEA1Q34338102-09ED6458-5663-459B-9CC1-97F9A1F4242FQ34343316-DA395D1A-CFCA-4DCE-AD87-9562F7912E09Q34704583-2550DBA2-92E0-4DD3-ADB9-10B3CDA68EF4Q35114977-286DB5BD-7B8D-4ECF-BE35-2E10F9DE61B4Q35558853-4072475A-E537-4AF4-AD4D-0636C1390091Q35677114-0AD27461-0124-4948-A8C4-11BEF02745B5Q35781620-783ED31D-2B3E-48DB-A656-CE444B4699F0Q35921757-6412320C-1D95-4383-BEBB-D0599D58A903Q36015557-290B5A48-86FC-4699-AD76-E2F70A5E28BAQ36141199-781AA44E-FD95-45AE-917D-80BABC83EB98Q36141347-E13C1F5C-7CA3-46B0-87EA-A7619BABD4D1Q36168690-3B5E6948-33A5-4351-95F8-50B912BE4752Q36494598-9072626E-B6BA-4739-9E5E-559DD24AA3B3Q36530069-80CE7611-0D88-4BBE-95AC-1D3914B8B54FQ36584458-A0E0B070-D8D1-4145-B604-22D14E63CADDQ36647788-C35E84B2-0C0A-414C-A162-CF96986A6015Q36666212-5B354507-DC96-42FF-B0BE-2EFDBFB322ADQ36673541-F9DF4A34-5796-4088-8337-78AE6C33E6E2Q36713626-06AFDA3E-8B10-4908-9FE4-37C99A6B309FQ36773259-D8BFEE41-3F90-4BCA-BEDC-D4DD4D92FAE6Q37171206-290A1F67-4E49-44A8-8757-F5C71A8B637FQ37221413-2C5D3EA7-6D5F-4331-AC89-0ABFCC43931AQ37496083-FB92E60B-4984-4DA0-8D73-698FCDD42D37Q37612726-F7A45964-746D-4841-9836-5D4FFF6D0B04Q38136461-E4D2E670-6E77-48EC-A806-C1DC3CD2EF33Q38226781-ED8B1A58-0406-420E-822D-3F1DC35F844CQ38468459-7BCE37FD-AB39-4093-9318-A27E7976041CQ38476355-2CDFF749-572A-4EA2-87BD-E07802458631Q38498903-B38B1E28-3C18-42A2-A3BF-02C1271D8E56Q38646376-90D4A7FB-5700-45DA-A2D3-E6BFE419861FQ38961619-F5FA349A-294B-47CD-A1DC-6FFCD83A39BC
P50
description
researcher
@en
wetenschapper
@nl
name
M R Reynolds
@en
M R Reynolds
@nl
type
label
M R Reynolds
@en
M R Reynolds
@nl
prefLabel
M R Reynolds
@en
M R Reynolds
@nl
P106
P31
P496
0000-0001-8675-8186